Affiliation:
1. Bandırma Onyedi Eylül University
Abstract
Abstract
Background and aims: The purpose of this study is to determine which anthropometric measurement and ratio (BMI, waist circumference, hip circumference, waist-to-hip ratio, neck circumference, waist-height ratio, body shape index, body roundness index, visceral adiposity index) is a better indicator in healthy individuals with NAFLD and their biochemical parameters.
Methods: The study included 41 healthy persons diagnosed with non-alcoholic fatty liver disease between the ages of 30-64 in the gastroenterology outpatient clinic of Ankara Gülhane Training and Research Hospital. In the study, subjects were interviewed face-to-face using a questionnaire form that asked about their socio-demographic traits, anthropometric measurements, and biochemical markers.
Results: Individuals with NAFLD had greater triglyceride, VLDL cholesterol, AST, ALT, and GGT levels than healthy people, as well as lower HDL cholesterol levels (p<0,05). persons with NAFLD had higher averages of body weight, BMI, waist circumference, waist/height, hip circumference, waist/hip, neck circumference, body fat mass, body shape index, body roundness index, and visceral fat index than healthy persons (p<0,05). Waist circumference, BMI, waist/height ratio, body roundness index, and visceral adiposity index are the anthropometric parameters with the greatest performance requirements that can be employed in persons with NAFLD.
Conclusion: Conclusion; It is believed that following patients at risk for NAFLD under the supervision of dietitians and using these anthropometric measurements will play a useful role in preventing the disease's course, progression, and consequences.
ClinicalTrials.gov Identifier: NCT05810506.
Publisher
Research Square Platform LLC
Reference34 articles.
1. Vernon G, Baranova A, YounossI ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults. Volume 34. Alimentary pharmacology & therapeutics; 2011. pp. 274–85. 3.
2. NASH Çalıştayı Sonuç Raporu. https://www.turkdiab.org/admin/PICS/webfiles/NASH_2018_elit.pdf. 2018.
3. The prevalence of non-alcoholic fatty liver disease in healthy young persons;Okur G;North Clin Istanbul,2016
4. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis;Watanabe S;J Gastroenterol,2015
5. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes;Younossi Zm, Koenig AB;Hepatology,2016